Despite a record number of large deals across the pharmaceutical and biotechnology landscape, market indicators are pointing toward a noticeable shift in the appetite for global deal-making across the industry. As the pool of high-valued assets becomes smaller, will signs point to a drastic increase in smaller deals for larger pharma companies looking to solidify their balance sheets across core therapeutic areas? How does a strong public market with a well-capitalized pool of young biotech targets that don’t need to be forced into an early buyout impact this hypothetical M&A shift? This session will feature experienced voices explaining the public perspective for a potentially active year within pharma and biotech deal-making.
Ori Solomon, Partner at Morrison & Foerster
Kimberly Nearing, Managing Director, Head of Life Sciences, Cedrus Group; Regional Leader for BayHelix's NY/NJ/PA Chapters
Andrew Gitkin, Managing Director and Co-Head of Healthcare Investment Banking, Raymond James
E. Eric Tokat, Partner Centerview Partners LLC
Philip Ross, Vice Chairman, Healthcare Investment Banking, J.P. Morgan